Rapamycin News and Research

RSS

Rapamycin is a drug used to prevent the rejection of organ and bone marrow transplants by the body. Rapamycin is an antibiotic that blocks a protein involved in cell division and inhibits the growth and function of certain T cells of the immune system involved in the body's rejection of foreign tissues and organs. It is a type of immunosuppressant and a type of serine/threonine kinase inhibitor. Rapamycin is now called sirolimus.

Cabozantinib extends advanced RCC overall survival

Patients with advanced or metastatic renal cell carcinoma derive a significant overall survival benefit from second-line treatment with the multi-tyrosine kinase inhibitor cabozantinib relative to everolimus.

18 Jun 2016

Researchers identify lymphatic endothelial lineage that shows potential for new anti-cancer treatment

Identifying the cell of origin is crucial to understanding how a tumor develops and metastasizes and for developing targeted therapies.

8 Jun 2016

Myricitrin may play role in preventing neuronal degeneration in Parkinson's disease

A new study has shown that myricitrin, a flavinoid with antioxidant and anti-inflammatory activity that is present inedible plants and fruit, can protect mouse brains from the loss of dopamine-producing neurons caused by neurotoxicity.

7 Jun 2016

New drugs show promise as first antidote for radiation exposure

University of Virginia School of Medicine researchers have identified promising drugs that could lead to the first antidote for radiation exposure that might result from a dirty bomb terror attack or a nuclear accident such as Chernobyl.

2 Jun 2016

ANK3 and other genes may play key role in affecting mood, stress and longevity

The visible impacts of depression and stress that can be seen in a person's face -- and contribute to shorter lives -- can also be found in alterations in genetic activity, according to newly published research.

24 May 2016

Rapamycin drug could target neural damage linked to Leigh syndrome

Salk Institute scientists showed how an FDA-approved drug boosts the health of brain cells by limiting their energy use. Like removing unnecessary lighting from a financially strapped household to save on electricity bills, the drug--called rapamycin--prolongs the survival of diseased neurons by forcing them to reduce protein production to conserve cellular energy.

27 Apr 2016

Existing cancer drugs may be able to help people with enlarged heart cells

UT Southwestern Medical Center cardiology researchers have identified molecular ties between the growth of cancer cells and heart cells that suggest existing cancer drugs may be able to help those with enlarged heart cells -- a condition that can lead to heart attacks and stroke.

18 Apr 2016

Ariste Medical develops drug-eluting mesh for more effective open hernia repair

Ariste Medical has revealed new research outlining the company’s novel method for addressing medical device failure in open ventral hernia repair.

12 Apr 2016

Rice university researchers uncover elusive lung cancer cells

Researchers at Rice University and the University of Texas MD Anderson Cancer Center have uncovered a trick used by lung cancer cells to hide from the body's immune system.

3 Mar 2016

Beiging of white fat could be harnessed to combat diabetes

Researchers are getting closer to learning how to turn white fat cells into brown fat cells, in a process called "beiging," to bring down blood sugar levels and fight diabetes. The team, led by Joseph Baur, PhD, an assistant professor of Physiology in the Perelman School of Medicine at the University of Pennsylvania published their findings this month in the journal Diabetes.

18 Feb 2016

Beige-fat formation could be harnessed to fight diabetes

Researchers are getting closer to learning how to turn white fat cells into brown fat cells, in a process called "beiging," to bring down blood sugar levels and fight diabetes.

17 Feb 2016

Boosting intrinsic growth programs can enhance axon regeneration of injured neurons

Damage to axons in the central nervous system (CNS) typically results in permanent functional deficits. Boosting intrinsic growth programs can dramatically augment the axon regeneration of injured neurons. If injured neurons can regenerate sufficient number of axons, the CNS may recover and overcome such functional deficits.

11 Feb 2016

Sirolimus chemoprevention supported in organ transplant recipients

In solid-organ transplant recipients diagnosed with cancer post-transplant, treatment with sirolimus reduces the risk of developing a subsequent skin cancer, US investigators report in JAMA Dermatology.

29 Jan 2016

Study outlines new model to help predict age-related response to hepatitis B vaccine

Physicians have known for years that patients respond differently to vaccines as they age. There may soon be a new way to predict and enhance the effectiveness of vaccinations, in particular the hepatitis B vaccine.

20 Jan 2016

Combination therapy can help overcome endocrine resistance in women with advanced breast cancer

Data collected in Japanese and Korean patients included in the global PALOMA3 trial provides evidence that combining palbociclib with fulvestrant is an effective strategy to overcome endocrine resistance in women with hormone receptor positive (HR+), HER2 negative (HER2-) advanced breast cancer.

20 Dec 2015

Researchers elucidate structure of mTORC1 protein

For a long time it has been known that the protein TOR - Target of Rapamycin - controls cell growth and is involved in the development of diseases such as cancer and diabetes. Researchers at the University of Basel's Biozentrum together with scientists from ETH Zurich have now examined the structure of mammalian TOR complex 1 (mTORC1) in more detail.

18 Dec 2015

VCU Massey Cancer Center scientists reveal signaling process that leads to excessive growth of cancer

The gene p53 has been described as the "guardian of the genome" due to its prominent role in preventing genetic mutations. More than half of all cancers are thought to originate from p53 mutations or loss of function, and now a recent study by VCU Massey Cancer Center scientist Richard Moran, Ph.D., explains why.

15 Dec 2015

$Ibrutinib ‘new standard’ for relapsed, refractory mantle cell lymphoma$